Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Sep;16(5):391-5.

Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease

S S Xu  1 , Z X Gao, Z Weng, Z M Du, W A Xu, J S Yang, M L Zhang, Z H Tong, Y S Fang, X S Chai, et al.
Affiliations
  • PMID: 8701750
Free article
Clinical Trial

Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease

S S Xu et al. Zhongguo Yao Li Xue Bao. 1995 Sep.
Free article

Abstract

Aim: To evaluate the efficacy and safety of tablet huperzine-A (Hup) in patients with Alzheimer's disease.

Methods: Using multicenter, prospective, double-blind, parallel, placebo controlled and randomized method, 50 patients were administered orally 0.2 mg (4 tablets) Hup and 53 patients were given po 4 tablets of placebo bid for 8 wk. All patients were evaluated with Wechsler memory scale, Hasegawa dementia scale, mini-mental state examination scale, activity of daily living scale, treatment emergency symptom scale, and measured with BP, HR, ECG, EEG, ALT, AKP, BUN, Cr, Hb, WBC, and urine routine.

Results: About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions. The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05). No severe side effect was found.

Conclusion: Hup is a promising drug for symptomatic treatment of Alzheimer's disease.

PubMed Disclaimer

LinkOut - more resources